Effect of Genistein on Apoptosis and Proliferation of Hepatocellular Carcinoma Hepa1‑6 Cell Line

Masumeh Sanaei, Fraidoon Kavoosi, Ali Valiani, Mohamed Amin Ghobadifar

Abstract


Background: One of the main causes of mortality is hepatocellular carcinoma (HCC) which accounts for the third leading cause of deaths and one in forty deaths worldwide. The flavonoids, natural antioxidant compounds, account for a major group of polyphenolic compounds. One of the major isoflavones in soybean is genistein (GE) which can inhibit proliferation and induce apoptosis. Isoflavones, major type of phenolic materials, derived from dietary plants and medicinal herbs play
a signifcant role in cancer prevention and treatment. Correlation between dietary habits and cancer risk including breast, prostate, and colon cancer has been reported. Various bioactivities of these compounds such as anticarcinogenic and antioxidant are responsible for their chemopreventive
activities by which induce migration, proliferation, cell cycle arrest, and apoptosis. GE, one of the major isoflavones, is considered as a potent chemopreventive agent against cancer. The aim of this study was to investigate the inhibitory and apoptotic effects of GE on HCC Hepa1‑6 cell line.

Methods: Cell viability assay and cell cycle analysis with flow cytometry were used to evaluate proliferative and apoptotic effect GE.

Results: GE inhibited the growth of Hepa1‑6 cells and induced apoptosis with a concentration and time‑dependent fashion. During GE treatment for 24, the half maximal inhibitory concentration (IC50) was 20 μM, and the maximum inhibition of cell growth was 52% (P < 0.01). The percentage of apoptotic cells with a concentration of 20 μM of GE after 24, 48, and 72 h was 35, 42, and 65%, respectively (P < 0.01).

Conclusions: Our fnding clearly indicated that GE can signifcantly inhibit proliferation of hepatocellular carcinoma Hepa 1‑6 cell line and induce apoptosis in this cell line.

Keywords: Apoptosis, genistein, hepatocellular carcinoma, proliferation


Full Text:

PDF

References


Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world

cancer burden: Globocan 2000. Int J Cancer 2001;94:153‑6.

Curado MP, Edwards B, Shin HR, Storm H, Ferlay J,

Heanue M, et al. Cancer incidence in five continents. IARC Sci

Publ 2007;9:898‑905.

Harborne JB, Williams CA. Advances in flavonoid research since

Phytochemistry 2000;55:481‑504.

Herrmann K. Flavonols and flavones in food plants: A review.

J Food Technol 1976;11:433‑48.

Kühnau J. The flavonoids. A class of semi‑essential food

components: Their role in human nutrition. World Rev Nutr Diet

;24:117‑91.

Crozier A, Burns J, Aziz AA, Stewart AJ, Rabiasz HS,

Jenkins GI, et al. Antioxidant flavonols from fruits, vegetables

and beverages: Measurements and bioavailability. Biol Res

;33:79‑88.

Kefford JF, Chandler BV, editors. The Chemical Constituents of

Citrus Fruits. New York: Academic Press; 1970.

Wesley F Taylor, Ehsan Jabbarzadeh. The use of natural products

to target cancer stem cells. Am J Cancer Res 2017;7:1588‑1605.

Adlercreutz H, Honjo H, Higashi A, Fotsis T, Hämäläinen E,

Hasegawa T, et al. Urinary excretion of lignans and isoflavonoid

phytoestrogens in Japanese men and women consuming a

traditional Japanese diet. Am J Clin Nutr 1991;54:1093‑100.

Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S,

Itoh N, et al. Genistein, a specific inhibitor of tyrosine‑specific

protein kinases. J Biol Chem 1987;262:5592‑5.

Gu Y, Zhu CF, Dai YL, Zhong Q, Sun B. Inhibitory effects of

genistein on metastasis of human hepatocellular carcinoma.

World J Gastroenterol 2009;15:4952‑7.

Sanaei M, Kavoosi F, Arezoo M. Apoptotic effect of genistein on

hepatocellular carcinoma HepG 2 cell line. Glob J Med Res Stud 2016;3:1‑8.

Dastjerdi MN, Kavoosi F, Valiani A, Esfandiari E, Sanaei M,

Sobhanian S, et al. Inhibitory effect of genistein on PLC/PRF5

hepatocellular carcinoma cell line. Int J Prev Med 2015;6:54.

Adlercreutz CH, Goldin BR, Gorbach SL, Höckerstedt KA,

Watanabe S, Hämäläinen EK, et al. Soybean phytoestrogen

intake and cancer risk. J Nutr 1995;125 3 Suppl:757S‑70S.

Park OJ, Surh YJ. Chemopreventive potential of epigallocatechin

gallate and genistein: Evidence from epidemiological and

laboratory studies. Toxicol Lett 2004;150:43‑56.

Wang HK. The therapeutic potential of flavonoids. Expert Opin

Investig Drugs 2000;9:2103‑19.

Barnes S, Peterson TG. Biochemical targets of the isoflavone

genistein in tumor cell lines. Proc Soc Exp Biol Med

;208:103‑8.

Sarkar FH, Li Y. Soy isoflavones and cancer prevention. Cancer

Invest 2003;21:744‑57.

Qi W, Weber CR, Wasland K, Roy H, Wali R, Joshi S, et al.

Tumor suppressor FOXO3 mediates signals from the EGF

receptor to regulate proliferation of colonic cells. Am J Physiol

Gastrointest Liver Physiol 2011;300:G264‑72.

So FV, Guthrie N, Chambers AF, Moussa M, Carroll KK.

Inhibition of human breast cancer cell proliferation and delay

of mammary tumorigenesis by flavonoids and citrus juices. Nutr

Cancer 1996;26:167‑81.

Choi EJ, Kim GH. Antiproliferative activity of daidzein and

genistein may be related to ERα/c‑erbB‑2 expression in human

breast cancer cells. Mol Med Rep 2013;7:781‑4.

Fritz WA, Coward L, Wang J, Lamartiniere CA. Dietary

genistein: Perinatal mammary cancer prevention, bioavailability

and toxicity testing in the rat. Carcinogenesis 1998;19:2151‑8.

Lamartiniere CA, Zhao YX, Fritz WA. Genistein: Mammary

cancer chemoprevention, in vivo mechanisms of action, potential

for toxicity, and bioavailability in rats. J Womens Cancer

;2:11‑9.

Lamartiniere CA, Moore JB, Brown NM, Thompson R,

Hardin MJ, Barnes S. Genistein suppresses mammary cancer in

rats. Carcinogenesis 1995;16:2833‑40.

Murrill WB, Brown NM, Zhang JX, Manzolillo PA, Barnes S,

Lamartiniere CA. Prepubertal genistein exposure suppresses

mammary cancer and enhances gland differentiation in rats.

Carcinogenesis 1996;17:1451‑7.

Peterson G, Barnes S. Genistein and biochanin A inhibit the

growth of human prostate cancer cells but not epidermal

growth factor receptor tyrosine autophosphorylation. Prostate

;22:335‑45.

Wang J, Eltoum IE, Lamartiniere CA. Dietary genistein

suppresses chemically induced prostate cancer in Lobund‑Wistar

rats. Cancer Lett 2002;186:11‑8.

Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD,

Aspinall JO, et al. Prostate cancer in a transgenic mouse. Proc

Natl Acad Sci U S A 1995;92:3439‑43.

Gingrich JR, Greenberg NM. A transgenic mouse prostate cancer

model. Toxicol Pathol 1996;24:502‑4.

Gingrich JR, Barrios RJ, Kattan MW, Nahm HS,

Finegold MJ, Greenberg NM. Androgen‑independent prostate

cancer progression in the TRAMP model. Cancer Res

;57:4687‑91.

Mentor‑Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM,

Elgavish A. Genistein in the diet reduces the incidence of

poorly differentiated prostatic adenocarcinoma in transgenic

mice (TRAMP). Cancer Res 2001;61:6777‑82.

Shao ZM, Wu J, Shen ZZ, Barsky SH. Genistein exerts multiple

suppressive effects on human breast carcinoma cells. Cancer Res

;58:4851‑7.

Santibáñez JF, Navarro A, Martínez J. Genistein inhibits

proliferation and in vitro invasive potential of human prostatic

cancer cell lines. Anticancer Res 1997;17:1199‑204.

Traganos F, Ardelt B, Halko N, Bruno S, Darzynkiewicz Z.

Effects of genistein on the growth and cell cycle progression of

normal human lymphocytes and human leukemic MOLT‑4 and

HL‑60 cells. Cancer Res 1992;52:6200‑8.

Moore AB, Castro L, Yu L, Zheng X, Di X, Sifre MI, et al.

Stimulatory and inhibitory effects of genistein on human uterine

leiomyoma cell proliferation are influenced by the concentration.

Hum Reprod 2007;22:2623‑31.

Miodini P, Fioravanti L, Di Fronzo G, Cappelletti V. The two

phyto‑oestrogens genistein and quercetin exert different effects

on oestrogen receptor function. Br J Cancer 1999;80:1150‑5.

Zava DT, Duwe G. Estrogenic and antiproliferative properties

of genistein and other flavonoids in human breast cancer cells

in vitro. Nutr Cancer 1997;27:31‑40.

Nakamura H, Wang Y, Kurita T, Adomat H, Cunha GR, Wang Y.

Genistein increases epidermal growth factor receptor signaling

and promotes tumor progression in advanced human prostate

cancer. PLoS One 2011;6:e20034.